<DOC>
	<DOCNO>NCT00396682</DOCNO>
	<brief_summary>It show patient advanced HCC increase frequency CD4+CD25+ regulatory T cell . These cell might suppress tumor-specific immune response . Cyclophosphamide show reduce frequency CD4+CD25+ regulatory T cell . The aim study test treatment cyclophosphamide lead decrease frequency CD4+CD25+ regulatory T cell increase tumor specific immune response patient advance HCC .</brief_summary>
	<brief_title>Elimination CD4+CD25+ Regulatory T Cells Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>adequate WBC adequate liver kidney function immunodeficiency ECOG &lt; 2 advanced liver cirrhosis severe cardiopulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>HCC</keyword>
	<keyword>T cell</keyword>
</DOC>